Drug intelligence / Profile preview

SC-Islets

Development stage: Preclinical
Lead developer: Vertex
Modality: Stem Cell Therapies → Cell Therapies
Administration: Subcutaneous, Intraportal, Intramuscular, Under-kidney-capsule (renal Subcapsular)

Overview

SC-Islets is a stem cell-derived islet therapy initially developed by Semma Therapeutics and later acquired by Vertex Pharmaceuticals. This therapy is designed for the treatment of type 1 diabetes, aiming to replace the insulin-producing cells that are lost in the disease. The underlying technology was exclusively licensed from Harvard University. Development efforts have focused on scaling manufacturing and creating an immune-protective delivery device to advance the product candidate into clinical trials and achieve clinical proof-of-concept.

Other names: SC-Islet therapySC-Islet technology

Beyond the preview

Go deeper on SC-Islets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SC-Islets.

Explore the full profile